{
    "nctId": "NCT04368442",
    "briefTitle": "Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation",
    "officialTitle": "Epidemiologic Evaluation and Clinical Outcomes for HER2-negative Metastatic Breast Cancer (MBC) Patients With Germline BRCA1 and 2 Pathogenic Mutation in Korea",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer Metastatic",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 583,
    "primaryOutcomeMeasure": "Progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 20 years old\n* Histologically confirmed, unresectable locally advanced or metastatic breast invasive carcinoma\n* Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer\n* Germline mutational status of BRCA1 and/or BRCA2 can be known or unknown\n* Signed written informed consent\n* The patient is regarded as good candidate for active palliative management at time of enrollment. The patient with terminal cancer which is not appropriate for further endocrine treatment or chemotherapy cannot be enrolled to this study.\n\nExclusion Criteria:\n\n* HER2 positive breast cancer\n* Amenable to curative surgery",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}